Hematology TimesAntibody has ‘very promising activity’ in rel/ref CTCLFebruary 15, 2018Lymphoma & Plasma Cell DisordersNon-Hodgkin Lymphoma
Hematology NewsA view from the bridge to transplant for PTCLFebruary 14, 2018T Cell LymphomasLymphoma & Plasma Cell DisordersAggressive Lymphomas
Oncology PracticeThe T-cell repertoire in NSCLC: Therapeutic implicationsFebruary 14, 2018Lung CancerImmuno-oncology
Oncology PracticeEnzalutamide shines in nonmetastatic castration-resistant prostate cancerFebruary 13, 2018Genitourinary Cancer
Oncology PracticeStudy explores biological implications of MHC-II expression in tumor cellsFebruary 13, 2018Immuno-oncology
Hematology TimesDrug appears safe and active in PTCL, CTCLFebruary 13, 2018Lymphoma & Plasma Cell DisordersNon-Hodgkin Lymphoma
Hematology TimesFDG PET can’t replace BM biopsy, study suggestsFebruary 12, 2018Lymphoma & Plasma Cell DisordersNon-Hodgkin Lymphoma
Hematology TimesInhibitor provides clinical improvement in MFFebruary 12, 2018Lymphoma & Plasma Cell DisordersNon-Hodgkin Lymphoma
Oncology PracticeBladder cancer: Two chemoradiation therapy regimens on par for muscle-invasive diseaseFebruary 10, 2018Genitourinary Cancer
Oncology PracticeERV expression may predict response to immune checkpoint blockade in ccRCC, other solid tumorsFebruary 9, 2018Renal Cell CarcinomaImmunotherapy
Hematology NewsPromising outcomes of thrombolysis for caval extension of iliofemoral DVTFebruary 9, 2018Thrombosis
Hematology NewsGetting hematologic cancer drugs on the fast trackFebruary 9, 2018T Cell LymphomasAggressive Lymphomas
Hematology NewsT-cell lymphoma therapies on the horizonFebruary 9, 2018T Cell LymphomasAggressive LymphomasLymphoma & Plasma Cell Disorders
Hematology TimesDrug may be option for B- and T-cell lymphomasFebruary 9, 2018Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive Lymphomas
